How regenerative medicine M&A performed in the pharmaceutical industry in Q2 2023

In value terms, regenerative medicine-related deal activity remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 300% in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Evercore; Guggenheim Partners; Houlihan Lokey with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Goodwin Procter; Cooley; Gibson, Dunn & Crutcher with 2, 1, 1 deals respectively.

For further understanding of GlobalData’s Regenerative Medicine in Medical – Thematic Research, buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.

Innovative dementia cost model to aid families and shape health policy

An A-list of researchers from across USC is building a dementia cost model that will generate comprehensive national, annual estimates of the cost of dementia

June 29, 2024

Shared community spaces in rural communities may promote healthy aging among older, non-white adults

Millions of Americans over the age of 65 lack access to the social and emotional support they need for healthy aging, according to the Centers

June 20, 2023

BAKX Therapeutics to shut down after ‘scientific challenges’ and financing doldrums

BAKX Therapeutics will shut down by Aug. 1, ending a “Thelma and Louise” approach to cancer small molecules after scientific, financing and timeline challenges upended

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.